210539-05-2

Basic information

• Product Name: 1,6-Naphthyridine, 2-chloro-5,6,7,8-tetrahydro-
• Synonyms: 1,6-Naphthyridine, 2-chloro-5,6,7,8-tetrahydro-;2-chloro-5,6,7,8-tetrahydro-[1,6]naphthyridine;2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine hydrochloride;1,6-phthyridine, 2-chloro-5,6,7,8-tetrahydro-
• CAS NO: 210539-05-2
• Molecular Formula: C8H9ClN2
• Molecular Weight: 168.62346
• Product Categories: CHIRAL CHEMICALS;Heterocycle-Pyridine series
• Mol File: 210539-05-2.mol

Chemical Properties

• Boiling Point: 284.822 °C at 760 mmHg
• Flash Point: 126.056 °C
• Appearance: /
• Density: 1.227g/cm³
• Refractive Index: 1.604
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 7.21±0.20(Predicted)
• CAS DataBase Reference: 1,6-Naphthyridine, 2-chloro-5,6,7,8-tetrahydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,6-Naphthyridine, 2-chloro-5,6,7,8-tetrahydro-(210539-05-2)
• EPA Substance Registry System: 1,6-Naphthyridine, 2-chloro-5,6,7,8-tetrahydro-(210539-05-2)

Safety Data

• Hazardous Substances Data: 210539-05-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1,6-Naphthyridine, 2-chloro-5,6,7,8-tetrahydrois used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with diverse biological activities.
Used in Agrochemical Industry:
In the agrochemical sector, 1,6-Naphthyridine, 2-chloro-5,6,7,8-tetrahydrois utilized as a building block in the creation of agrochemicals, enhancing the development of substances with potential applications in agriculture.
Used in Organic Chemistry Research:
As a research reagent, 1,6-Naphthyridine, 2-chloro-5,6,7,8-tetrahydrois employed in organic chemistry for its structural and property attributes, facilitating the exploration and understanding of chemical reactions and mechanisms.

InChI:InChI=1/C8H9ClN2/c9-11-4-2-7-5-10-3-1-8(7)6-11/h1,3,5H,2,4,6H2

Upstream product

• 1151665-15-4 2-chloro-7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester 
• 210539-04-1 6-benzyl-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine 

Downstream Products

• 1149333-40-3 2-amino-7,8-dihydro-1,6-naphthyridin-6(5H)-carboxylic acid tert-butyl ester 

Relevant articles and documents

PD-1/PD-L1 INHIBITORS

Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR4 or N; Y is CR4 or N, provided that Y is N only if X is N; R1 is Formulae (A) or (B); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, R3, R4, L1, R1a, R1b, R1c, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS

The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia

Compounds of formula I, STR1whereinR 1 represents C 1-4 alkoxy optionally substituted by one or more fluorine atoms;R 2 represents H or C 1-6 alkoxy optionally substituted by one or more fluorine atoms;R 3 represents a 5- or 6-membered heterocyclic ring, the ring being optionally substituted;R 4 represents a 4-, 5-, 6-, or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic ring, the ring system as a whole being optionally substituted;X represents CH or N; andL is absent,or represents a cyclic group of formula Ia, STR2or represents a chain of formula Ib, STR3and pharmaceutically acceptable salts thereof, are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.